466 related articles for article (PubMed ID: 22356640)
1. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.
Tack J; Camilleri M; Chang L; Chey WD; Galligan JJ; Lacy BE; Müller-Lissner S; Quigley EM; Schuurkes J; De Maeyer JH; Stanghellini V
Aliment Pharmacol Ther; 2012 Apr; 35(7):745-67. PubMed ID: 22356640
[TBL] [Abstract][Full Text] [Related]
2. An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954.
Beattie DT; Higgins DL; Ero MP; Amagasu SM; Vickery RG; Kersey K; Hopkins A; Smith JA
Vascul Pharmacol; 2013 Jan; 58(1-2):150-6. PubMed ID: 23201772
[TBL] [Abstract][Full Text] [Related]
3. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.
Manabe N; Wong BS; Camilleri M
Expert Opin Investig Drugs; 2010 Jun; 19(6):765-75. PubMed ID: 20408739
[TBL] [Abstract][Full Text] [Related]
4. Inotropic effects of prokinetic agents with 5-HT(4) receptor agonist actions on human isolated myocardial trabeculae.
Chai W; Chan KY; de Vries R; van den Bogeardt AJ; de Maeyer JH; Schuurkes JA; Villalón CM; Saxena PR; Danser AH; MaassenVanDenBrink A
Life Sci; 2012 Apr; 90(13-14):538-44. PubMed ID: 22326501
[TBL] [Abstract][Full Text] [Related]
5. 5-HT4 receptor agonists: similar but not the same.
De Maeyer JH; Lefebvre RA; Schuurkes JA
Neurogastroenterol Motil; 2008 Feb; 20(2):99-112. PubMed ID: 18199093
[TBL] [Abstract][Full Text] [Related]
6. The in vitro pharmacology and non-clinical cardiovascular safety studies of a novel 5-HT
Tsubouchi T; Kunimatsu T; Tsujimoto S; Kiyoshi A; Katsura Y; Oku S; Chihara K; Mine Y; Yamada T; Shimizu I; Bando K
Eur J Pharmacol; 2018 May; 826():96-105. PubMed ID: 29501863
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel.
Potet F; Bouyssou T; Escande D; Baró I
J Pharmacol Exp Ther; 2001 Dec; 299(3):1007-12. PubMed ID: 11714889
[TBL] [Abstract][Full Text] [Related]
8. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.
Beattie DT; Armstrong SR; Shaw JP; Marquess D; Sandlund C; Smith JA; Taylor JA; Humphrey PP
Naunyn Schmiedebergs Arch Pharmacol; 2008 Jul; 378(1):139-47. PubMed ID: 18408918
[TBL] [Abstract][Full Text] [Related]
9. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation.
Shin A; Camilleri M; Kolar G; Erwin P; West CP; Murad MH
Aliment Pharmacol Ther; 2014 Feb; 39(3):239-53. PubMed ID: 24308797
[TBL] [Abstract][Full Text] [Related]
10. Translating 5-HT receptor pharmacology.
Sanger GJ
Neurogastroenterol Motil; 2009 Dec; 21(12):1235-8. PubMed ID: 19906028
[TBL] [Abstract][Full Text] [Related]
11. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.
Smith JA; Beattie DT; Marquess D; Shaw JP; Vickery RG; Humphrey PP
Naunyn Schmiedebergs Arch Pharmacol; 2008 Jul; 378(1):125-37. PubMed ID: 18415081
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of tegaserod in irritable bowel syndrome management.
Berardi RR
J Am Pharm Assoc (2003); 2004; 44(1):41-51. PubMed ID: 14965152
[TBL] [Abstract][Full Text] [Related]
13. Thorough QT/QTc Study Shows That a Novel 5-HT
Hamatani T; Noda N; Takagaki T; Yodo Y; Kawai H; Kakuyama H; Kaji Y; Fujio Y
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):938-951. PubMed ID: 32087003
[TBL] [Abstract][Full Text] [Related]
14. Measurement of 5-HT4 receptor-mediated esophageal responses by digital sonomicrometry in the anesthetized rat.
Armstrong SR; McCullough JL; Beattie DT
J Pharmacol Toxicol Methods; 2006; 53(3):198-205. PubMed ID: 16168678
[TBL] [Abstract][Full Text] [Related]
15. The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities.
Toga T; Kohmura Y; Kawatsu R
J Pharmacol Sci; 2007 Oct; 105(2):207-10. PubMed ID: 17928736
[TBL] [Abstract][Full Text] [Related]
16. Use of prucalopride in adults with chronic idiopathic constipation.
Vijayvargiya P; Camilleri M
Expert Rev Clin Pharmacol; 2019 Jul; 12(7):579-589. PubMed ID: 31096799
[No Abstract] [Full Text] [Related]
17. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.
Ford AC; Brandt LJ; Young C; Chey WD; Foxx-Orenstein AE; Moayyedi P
Am J Gastroenterol; 2009 Jul; 104(7):1831-43; quiz 1844. PubMed ID: 19471254
[TBL] [Abstract][Full Text] [Related]
18. Commentary: towards a cardiac safe prokinetic.
Scarpignato C
Aliment Pharmacol Ther; 2012 May; 35(10):1243-4. PubMed ID: 22500472
[No Abstract] [Full Text] [Related]
19. A 5-HT4-like receptor in human right atrium.
Kaumann AJ; Sanders L; Brown AM; Murray KJ; Brown MJ
Naunyn Schmiedebergs Arch Pharmacol; 1991 Aug; 344(2):150-9. PubMed ID: 1658664
[TBL] [Abstract][Full Text] [Related]
20. Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation.
Wong BS; Manabe N; Camilleri M
Clin Exp Gastroenterol; 2010; 3():49-56. PubMed ID: 21694846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
